We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BioDelivery Inks New Contract with CVS/Caremark, Shares Up
Read MoreHide Full Article
BioDelivery Sciences International, Inc.’s shares increased more than 5% after the company announced an agreement with CVS/Caremark, a subsidiary of CVS Health Corporation (CVS - Free Report) . The agreement will extend access to BioDelivery’s pain management product Belbuca and opioid dependence product Bunavail through 2020.
The company has also separately announced that Belbuca prescription sales had reached its highest point of 1,657 prescriptions this month. Per the Symphony Health data, this publicized figure has exceeded the previous peak from Dec 2016. The new managed care contract with CVS/Caremark may expand the recent gains in prescriptions for Belbuca.
BioDelivery is presently exploring commercial options for for both Belbuca and Bunavail’s longer-term growth within and outside the U.S. The company is working on securing new or improved positioning on other managed care contracts either on an exclusive or preferred status. The new managed care contract with CVS/Caremark holds potential as it represents a significant portion of the covered lives in the U.S.
We remind investors that Belbuca was launched in Feb 2016 in the U.S. by Endo Pharmaceuticals . However in Jan 2017, BioDelivery reacquired worldwide rights to Belbuca from Endo. This was followed by a strategic decision announced by Endo in Dec 2016 to discontinue the commercial efforts for the U.S. branded pain business. As a result, the company started recording product revenues for Belbuca against royalties being recorded previously.
BioDelivery’s shares have significantly outperformed the Zacks classified Medical-Biomed/Genetics industry so far this year. Shares of the company rallied 57.1%, while the industry registered an increase of 10.5%.
Apart from the CVS/Caremark deal, BioDelivery is also pursuing additional managed care wins for Belbuca and is in contracting discussions with Cigna, ProCareRx, EnvisionRx, Envolve, Health Partners and Kaiser.
BioDelivery also continues to work on improving Bunavail’s performance. In the first quarter of 2017, Bunavail recorded 52.4% year-over-year surge in sales to $3.2 million. The improved prescription potential in new managed care contracts should boost sales and profitability of Bunavail further.
Regeneron’s earnings per share estimates increased from $10.16 to $10.52 for 2017 and from $10.90 to $12.10 over the last 60 days. The company has delivered positive earnings surprises in two of the four trailing quarters with an average beat of 0.45%.
Looking for Ideas with Even Greater Upside?
Today's investment ideas are short-term, directly based on our proven 1 to 3 month indicator. In addition, I invite you to consider our long-term opportunities. These rare trades look to start fast with strong Zacks Ranks, but carry through with double and triple-digit profit potential. Starting now, you can look inside our home run, value, and stocks under $10 portfolios, plus more. Click here for a peek at this private information >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
BioDelivery Inks New Contract with CVS/Caremark, Shares Up
BioDelivery Sciences International, Inc.’s shares increased more than 5% after the company announced an agreement with CVS/Caremark, a subsidiary of CVS Health Corporation (CVS - Free Report) . The agreement will extend access to BioDelivery’s pain management product Belbuca and opioid dependence product Bunavail through 2020.
.jpg)
The company has also separately announced that Belbuca prescription sales had reached its highest point of 1,657 prescriptions this month. Per the Symphony Health data, this publicized figure has exceeded the previous peak from Dec 2016. The new managed care contract with CVS/Caremark may expand the recent gains in prescriptions for Belbuca.
BioDelivery is presently exploring commercial options for for both Belbuca and Bunavail’s longer-term growth within and outside the U.S. The company is working on securing new or improved positioning on other managed care contracts either on an exclusive or preferred status. The new managed care contract with CVS/Caremark holds potential as it represents a significant portion of the covered lives in the U.S.
We remind investors that Belbuca was launched in Feb 2016 in the U.S. by Endo Pharmaceuticals . However in Jan 2017, BioDelivery reacquired worldwide rights to Belbuca from Endo. This was followed by a strategic decision announced by Endo in Dec 2016 to discontinue the commercial efforts for the U.S. branded pain business. As a result, the company started recording product revenues for Belbuca against royalties being recorded previously.
BioDelivery’s shares have significantly outperformed the Zacks classified Medical-Biomed/Genetics industry so far this year. Shares of the company rallied 57.1%, while the industry registered an increase of 10.5%.
Apart from the CVS/Caremark deal, BioDelivery is also pursuing additional managed care wins for Belbuca and is in contracting discussions with Cigna, ProCareRx, EnvisionRx, Envolve, Health Partners and Kaiser.
BioDelivery also continues to work on improving Bunavail’s performance. In the first quarter of 2017, Bunavail recorded 52.4% year-over-year surge in sales to $3.2 million. The improved prescription potential in new managed care contracts should boost sales and profitability of Bunavail further.
BioDelivery Sciences International, Inc. Price
BioDelivery Sciences International, Inc. Price | BioDelivery Sciences International, Inc. Quote
Zacks Rank & Key Picks
BioDelivery currently carries a Zacks Rank #3 (Hold). A better-ranked stock in healthcare sector is Regeneron Pharmaceuticals, Inc. (REGN - Free Report) , which sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Regeneron’s earnings per share estimates increased from $10.16 to $10.52 for 2017 and from $10.90 to $12.10 over the last 60 days. The company has delivered positive earnings surprises in two of the four trailing quarters with an average beat of 0.45%.
Looking for Ideas with Even Greater Upside?
Today's investment ideas are short-term, directly based on our proven 1 to 3 month indicator. In addition, I invite you to consider our long-term opportunities. These rare trades look to start fast with strong Zacks Ranks, but carry through with double and triple-digit profit potential. Starting now, you can look inside our home run, value, and stocks under $10 portfolios, plus more. Click here for a peek at this private information >>